Pseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial
and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed
over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained
market authorization. The understanding of P. aeruginosa pathogenesis and its virulence factors is essential in the identification
of immunogens that can be used for a P. aeruginosa vaccine. This review summarizes the present status of vaccine
development for this important pathogen.
Keywords: Cystic fibrosis, Clinical trials, Hospital infections, Immunity, Pseudomonas aeruginosa, Vaccines.
Rights & PermissionsPrintExport